Effect of Chlormadinone Acetate Treatment on Canine Prostatic Hyperplasia
Yoshihiko KOJIMA, Shizuo KAWAKAMI, Masao Shino
Abstract
Open-access reader
Yoshihiko KOJIMA, Shizuo KAWAKAMI, Masao Shino
Abstract
Open-access reader
Dogs with prostatic hyperplasia were treated with either oral administration or subcutaneous implantation of chlormadinone acetate (CMA). In 4 orally treated (1-2mg/kg/day for 9 to 35 days) cases blood CMA levels increased to 94 to 280ng/ml immediately after starting the treatment, decreasing shortly after stopping administration. In 5 cases given CMA implantation (10mg) blood levels were maintained below 10ng/ml for a year or longer. In all treated cases the prostate decreased in size and most clinical signs disappeared. The blood cortisol and progesterone levels decreased immediately after starting the treatment, while no remarkable changes were observed on testosterone and estradiol levels.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Dogs with prostatic hyperplasia were treated with either oral administration or subcutaneous implantation of chlormadinone acetate (CMA). In 4 orally treated (1-2mg/kg/day for 9 to 35 days) cases blood CMA levels increased to 94 to 280ng/ml immediately after starting the treatment, decreasing shortly after stopping administration. In 5 cases given CMA implantation (10mg) blood levels were maintained below 10ng/ml for a year or longer. In all treated cases the prostate decreased in size and most clinical signs disappeared. The blood cortisol and progesterone levels decreased immediately after starting the treatment, while no remarkable changes were observed on testosterone and estradiol levels.
Key concepts: Chlormadinone acetate, Medicine, Hyperplasia, Testosterone (patch), Urology, Prostate, Internal medicine, Oral administration